{"id":"adefovir-adv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity / renal dysfunction"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Asthenia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Elevated creatinine"}]},"_chembl":{"chemblId":"CHEMBL922","moleculeType":"Small molecule","molecularWeight":"501.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adefovir dipivoxil is a prodrug that is converted to adefovir, which inhibits hepatitis B virus (HBV) reverse transcriptase and DNA polymerase. By blocking viral DNA synthesis, it reduces HBV replication and viral load in chronically infected patients. It is also active against HIV reverse transcriptase, though primarily developed for HBV.","oneSentence":"Adefovir is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:35.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"HBV with lamivudine resistance"}]},"trialDetails":[{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT00307242","phase":"PHASE4","title":"Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2005-06-17","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT01146808","phase":"PHASE1, PHASE2","title":"Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-03","conditions":"Hepatitis B, Liver Transplantation","enrollment":16},{"nctId":"NCT04724785","phase":"","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2020-12-01","conditions":"Sustained Virologic Response, Hepatitis B, Chronic","enrollment":10000},{"nctId":"NCT01300234","phase":"PHASE3","title":"Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-30","conditions":"Hepatitis B","enrollment":512},{"nctId":"NCT01521975","phase":"PHASE4","title":"A Two-year Study of Telbivudine in HBeAg Negative Hepatitis","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2011-01-01","conditions":"Hepatitis B, Chronic","enrollment":360},{"nctId":"NCT03253250","phase":"PHASE4","title":"The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2017-09-01","conditions":"Chronic Hepatitis b, Hepatic Carcinoma","enrollment":432},{"nctId":"NCT00116805","phase":"PHASE3","title":"A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-06","conditions":"Chronic Hepatitis B","enrollment":266},{"nctId":"NCT00117676","phase":"PHASE3","title":"A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-02","conditions":"Chronic Hepatitis B","enrollment":382},{"nctId":"NCT01732367","phase":"PHASE4","title":"TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA","status":"COMPLETED","sponsor":"Keimyung University Dongsan Medical Center","startDate":"2012-11","conditions":"Chronic Hepatitis B","enrollment":171},{"nctId":"NCT02327416","phase":"PHASE3","title":"A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2014-10","conditions":"Hepatitis B, Chronic","enrollment":300},{"nctId":"NCT02598063","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Hepatitis B, Chronic","enrollment":255},{"nctId":"NCT02560649","phase":"PHASE4","title":"An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2015-05","conditions":"Chronic Hepatitis B","enrollment":324},{"nctId":"NCT02075294","phase":"","title":"Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Ying-Jie Ji","startDate":"2010-01","conditions":"Hepatitis B, Chronic","enrollment":242},{"nctId":"NCT01597934","phase":"PHASE4","title":"Antiviral Efficacy of Switching to ETV Plus TDF","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-08","conditions":"Chronic Hepatitis B","enrollment":104},{"nctId":"NCT00158717","phase":"","title":"Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-04","conditions":"Hepatitis B","enrollment":107},{"nctId":"NCT00065507","phase":"PHASE3","title":"Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-08","conditions":"Hepatitis B","enrollment":195},{"nctId":"NCT00095121","phase":"PHASE3","title":"Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-06","conditions":"Chronic Hepatitis B","enrollment":173},{"nctId":"NCT00376259","phase":"PHASE3","title":"Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-01","conditions":"Hepatitis B","enrollment":43},{"nctId":"NCT00096785","phase":"PHASE3","title":"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-12","conditions":"Hepatitis B, Chronic Disease","enrollment":69},{"nctId":"NCT00316719","phase":"PHASE3","title":"Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01","conditions":"Chronic Hepatitis B","enrollment":105},{"nctId":"NCT00857675","phase":"PHASE3","title":"A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-12","conditions":"Chronic Hepatitis B","enrollment":480},{"nctId":"NCT00645294","phase":"PHASE1, PHASE2","title":"Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-02","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT00158704","phase":"NA","title":"Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2002-01","conditions":"Hepatitis B","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adefovir (ADV)","genericName":"Adefovir (ADV)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adefovir is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus. Used for Chronic hepatitis B infection, HBV with lamivudine resistance.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}